 comparison effects ipratropium bromide metaproterenol sulfate acute exacerbations COPD Thirty-two patients acute exacerbations chronic obstructive pulmonary disease following double-blind crossover study First time patients ipratropium bromide micrograms metaproterenol sulfate mg dose inhaler MDI device Inspirease minutes whichever medications phase phase Pulmonary function FVC time minutes phase treatment minutes phase treatment minutes start study Arterial blood gas samples entry study minutes phase medication groups age degree airway obstruction hypoxemia theophylline usage start study phase minutes pulmonary function groups ipratropium metaproterenol improvement phase treatment group Thirty minutes ipratropium small significant rise mm Hg metaproterenol inhalation mm Hg decline changes minutes acute exacerbations COPD ipratropium metaproterenol effective medications MDI device Inspirease ipratropium choice decline blood oxygenation